Perhaps the most anticipated FDA advisory committee meeting of 2010 has been the July 13-14 "rereview" of GlaxoSmithKline’s diabetes drug Avandia and particularly the drug's possible cardiovascular
risks.
"The Pink Sheet" DAILY set the stage with several in-depth articles exploring key issues leading up to the meeting and now is covering the committee's actions just as closely.
Get a free download of two of our most recent articles now, by going HERE.
"The Pink Sheet" DAILY will be providing continued Avandia coverage all week. Go to www.thepinksheetdaily.com to get a free trial subscription.
